Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Palivizumab
Related studies linked through entity extraction aliases.